Quick Answer: Kratom is not chemically an opioid, but its alkaloids act on the same mu-opioid receptors as opioid drugs, producing opioid-like effects, dependence, and withdrawal.
Kratom is not an opioid in the chemical sense. It is a plant, and its active compounds are structurally unrelated to morphine, oxycodone, or fentanyl.
Functionally, it behaves like one. Kratom’s alkaloids bind the same mu-opioid receptors that opioid drugs target, which is why it relieves pain, produces euphoria at higher doses, and causes an opioid-type withdrawal when someone stops.
That distinction sounds academic. It is not. It shapes how kratom is regulated, how it is marketed, and how people decide whether it is safe.
Here, we cover what kratom does at the receptor level, where it differs from conventional opioids, and why the answer matters for anyone who has become dependent on it.
Key Takeaways
- Kratom is not chemically an opioid. Its alkaloids are structurally unrelated to morphine and fentanyl.
- It acts on mu-opioid receptors, the same target as opioid drugs, which is why it produces opioid-like effects.
- Mitragynine makes up roughly two thirds of the alkaloid content in kratom leaf.
- Kratom’s receptor activity is biased in a way that may reduce respiratory depression compared with conventional opioids.
- Concentrated 7-OH products behave much closer to a conventional opioid than leaf does.
- The CDC’s overdose surveillance system tracks kratom as the only non-opioid substance with opioid-like properties.
- S2L helps you overcome dependence with professional support. Call 615.819.4175 or see how we can help.
What Makes a Drug an Opioid?
The word “opioid” gets used in two different ways, which is the source of most of the confusion.
By chemistry, opioids are compounds derived from or structurally related to the opium poppy: morphine and codeine naturally, oxycodone and hydrocodone semi-synthetically, fentanyl fully synthetically. Kratom fails this test. Its alkaloids are indole alkaloids from a plant in the coffee family, with a different molecular backbone.
By action, an opioid is anything that activates opioid receptors in the brain and body. Kratom passes this test clearly.
The FDA has described kratom’s compounds as opioid compounds on the basis of receptor activity. The DEA lists kratom as a Drug and Chemical of Concern without scheduling the leaf. NIDA describes it as a substance with both stimulant and opioid-like effects depending on dose.
None of those positions is contradictory. They are answering slightly different questions.
How Kratom Acts on Opioid Receptors
Kratom leaf contains more than 40 alkaloids. According to research compiled by Johns Hopkins investigators, mitragynine makes up approximately 66% of the total alkaloids in kratom leaves, and it does most of the work.
Mitragynine is a partial agonist at the mu-opioid receptor. Partial means it activates the receptor less completely than a full agonist like morphine, which produces a ceiling on some of its effects.
It is also described in the research as G-protein biased. Opioid receptors can signal through two pathways, and mitragynine engages one while largely leaving the other alone. The pathway it avoids is associated with respiratory depression, which is the mechanism behind most fatal opioid overdoses.
7-hydroxymitragynine is the other compound that matters. It binds the mu-opioid receptor far more strongly than mitragynine. In natural leaf it exists in trace amounts, typically under two percent of total alkaloids, so its role is limited. In concentrated products it dominates.
Kratom also interacts with adrenergic and serotonergic systems, which is where the stimulant-like effects at low doses come from. That mixed profile is what makes kratom’s pharmacology genuinely different from a conventional opioid, even though the dependence risk is real either way.
Kratom vs. Conventional Opioids
| Kratom leaf | Conventional opioids | |
| Chemical class | Indole alkaloids, coffee family plant | Poppy-derived, semi-synthetic, or synthetic |
| Mu-receptor activity | Partial agonist, G-protein biased | Full agonist for most |
| Low-dose effect | Stimulant-like alertness | Sedation |
| High-dose effect | Pain relief, sedation, euphoria | Pain relief, sedation, euphoria |
| Respiratory depression | Lower risk from leaf alone | Primary overdose mechanism |
| Dependence | Develops with regular use | Develops with regular use |
| Withdrawal | Opioid-type, generally milder than heroin | Opioid-type, severity varies by drug |
| FDA status | Not approved for any use | Approved for specific medical uses |
The row that matters most is the second-to-last. Whatever the chemistry says, regular use produces dependence, and stopping produces withdrawal that looks and feels like opioid withdrawal.
Why the Distinction Matters
For regulation. Because kratom is not chemically an opioid, it fell outside the scheduling system built for opioids. That is a large part of why it has been sold openly in retail shops while conventional opioids require a prescription.
For marketing. “Not an opioid” is technically accurate and functions as a safety claim in practice. Products are sold as natural alternatives to pain medication on exactly this basis.
For surveillance. The CDC’s State Unintentional Drug Overdose Reporting System records overdose deaths where an opioid contributed, and it makes one exception: substances with opioid-like properties. Kratom is currently the only substance in that category, which is a fairly direct statement about how public health agencies classify it in practice.
For the person using it. Someone who switched from prescription opioids to kratom to get off opioids has usually not left opioid receptor dependence behind. They have changed which compound is occupying the receptor.
The Self-Treatment Trap
The most common route into kratom dependence starts with conventional opioids.
Kratom blunts opioid withdrawal, and it does so well enough that many people find it genuinely useful. The problem is that relief comes from the same receptor activity that produced the original dependence.
Research has documented this in both directions. Some people use kratom as a step away from opioids. Others develop kratom dependence first and move toward opioids when kratom becomes unavailable or stops working.
Neither path is a character flaw. Both are what happens when a receptor system that has already adapted keeps getting activated.
Where anxiety or depression is part of why the substance was useful, dual diagnosis treatment addresses both together rather than one after the other.
Does Kratom Show Up on an Opioid Drug Test?
Standard 5-panel and 10-panel screens test for a defined list of substances, and kratom is not on it. Because mitragynine is structurally unrelated to morphine, it does not generally trigger opiate immunoassays.
Specialized tests can detect kratom alkaloids. These are ordered deliberately and are not part of routine employment screening.
The practical result is that kratom use is often invisible in clinical and workplace settings, which is one more reason it goes unaddressed for years.
What This Means for Withdrawal and Treatment
Because kratom acts on opioid receptors, stopping produces opioid-type withdrawal. Symptoms commonly begin 6 to 24 hours after the last dose, peak over the first few days, and ease across the following week.
Withdrawal from concentrated 7-OH products tends to be more intense than withdrawal from leaf, which matters as those products face federal restriction and supply becomes unreliable.
Treatment follows the same principles used for other opioid-type substance use disorders. It starts with an evaluation by a medical team, who determine whether a supervised kratom detox is needed and what it should involve.
If you are having thoughts of suicide or self-harm, call or text 988 to reach the Suicide and Crisis Lifeline. In an emergency, call 911.
Legal Status
Kratom leaf is not federally scheduled. On July 1, 2026, the DEA filed notices of intent to temporarily place 7-hydroxymitragynine above a specified threshold, along with three synthetic derivatives, into Schedule I. Those notices published July 6, 2026, and the earliest a temporary order could issue was August 5, 2026.
State law is a separate matter. Tennessee enacted Public Chapter 950 (Matthew Davenport’s Law), effective July 1, 2026, making it the eighth state to fully ban kratom. Possession is a Class A misdemeanor, and manufacture, delivery, and sale are a Class C felony.
S2L Recovery supports this legislation as a positive step for public health. If you live elsewhere, check your own state’s current statute.
Getting Help for Kratom Dependence
Kratom addiction is treated the way other opioid-type substance use disorders are treated. The physical dependence and the reason a person started using both need attention.
At S2L Recovery, we believe in restoring the whole person through God’s grace.
Treatment typically includes medically supervised detox when needed, a 42-day residential phase, and an optional 42-day extended-care phase based on clinical recommendations, program eligibility, and availability.
S2L’s medical team runs an established kratom detoxification protocol through our in-house medical detox program.
Many people arrive here having tried to solve one dependence with another, and carrying the discouragement that comes with it. Fear not, for I am with you; be not dismayed, for I am your God (Isaiah 41:10). Restoration is possible, and it does not depend on having done this perfectly.
Our approach is Christ-centered. Alongside individual therapy and family therapy, people work on the question underneath the substance: what it was managing, and what takes its place.
S2L Recovery serves men and women through separate programs at separate Tennessee locations. Both are open and accepting admissions.
To talk with our team about kratom addiction treatment, call 615.819.4175. You can also verify your insurance benefits first.
Frequently Asked Questions About Kratom and Opioids
Is kratom an opioid?
Not chemically. Kratom’s alkaloids are structurally unrelated to morphine or fentanyl. They do act on the same mu-opioid receptors, which is why kratom produces opioid-like effects, dependence, and withdrawal.
Is kratom considered an opioid?
Regulators treat it differently by context. The FDA has described kratom’s compounds as opioid compounds based on receptor activity, while the DEA lists kratom as a Drug and Chemical of Concern without scheduling the leaf.
Is kratom an opioid or an opiate?
Neither, strictly. Opiates come directly from the opium poppy and opioids are the broader chemical class. Kratom belongs to neither, though it acts on the same receptors.
What class of drug is kratom?
Kratom is a botanical product, not a scheduled controlled substance at the federal level. The DEA lists it as a Drug and Chemical of Concern, and the FDA has not approved it for any use.
Is kratom like an opioid in its effects?
At higher doses, yes. It produces pain relief, sedation, and euphoria. At lower doses it produces stimulant-like effects instead, which conventional opioids do not.
Will kratom show up on an opioid test?
Standard opioid screens do not detect kratom, because mitragynine is structurally unrelated to morphine. Specialized tests can identify kratom alkaloids but must be ordered specifically.
Is kratom safer than opioids?
Kratom leaf carries a lower risk of respiratory depression than conventional opioids, but it is unregulated, varies in potency, and produces dependence. Concentrated 7-OH products narrow that gap considerably.
Can kratom help with opioid withdrawal?
Many people use it that way, and it does blunt symptoms. It also frequently produces dependence of its own, because the relief comes from the same receptor activity.
Does insurance cover kratom addiction treatment?
Many PPO and some POS plans cover residential treatment for substance use disorders, including kratom dependence. S2L Recovery works with Aetna, Blue Cross Blue Shield, Cigna, United Healthcare, UMR, Prime Health, and other major insurance providers.
